Show simple item record

dc.contributor.authorRossello, Xavier 
dc.contributor.authorRodriguez-Sinovas, Antonio
dc.contributor.authorVilahur, Gemma
dc.contributor.authorCrisóstomo, Verónica
dc.contributor.authorJorge, Inmaculada 
dc.contributor.authorZaragoza, Carlos 
dc.contributor.authorZamorano, José L
dc.contributor.authorBermejo, Javier
dc.contributor.authorOrdoñez, Antonio
dc.contributor.authorBoscá, Lisardo
dc.contributor.authorVazquez, Jesus 
dc.contributor.authorBadimón, Lina
dc.contributor.authorSánchez-Margallo, Francisco Miguel
dc.contributor.authorFernández-Avilés, Francisco
dc.contributor.authorGarcia-Dorado, David
dc.contributor.authorIbanez, Borja
dc.identifier.citationSci Rep. 2019; 9(1):20290es_ES
dc.description.abstractDespite many cardioprotective interventions have shown to protect the heart against ischemia/reperfusion injury in the experimental setting, only few of them have succeeded in translating their findings into positive proof-of-concept clinical trials. Controversial and inconsistent experimental and clinical evidence supports the urgency of a disruptive paradigm shift for testing cardioprotective therapies. There is a need to evaluate experimental reproducibility before stepping into the clinical arena. The CIBERCV (acronym for Spanish network-center for cardiovascular biomedical research) has set up the "Cardioprotection Large Animal Platform" (CIBER-CLAP) to perform experimental studies testing the efficacy and reproducibility of promising cardioprotective interventions based on a pre-specified design and protocols, randomization, blinding assessment and other robust methodological features. Our first randomized, control-group, open-label blinded endpoint experimental trial assessing local ischemic preconditioning (IPC) in a pig model of acute myocardial infarction (n = 87) will be carried out in three separate sets of experiments performed in parallel by three laboratories. Each set aims to assess: (A) CMR-based outcomes; (B) histopathological-based outcomes; and (C) protein-based outcomes. Three core labs will assess outcomes in a blinded fashion (CMR imaging, histopathology and proteomics) and 2 methodological core labs will conduct the randomization and statistical analysis.es_ES
dc.description.sponsorshipGroups part of the CIBERCV receive competitive structural funding from the Insituto de Salud Carlos III (ISCiii) through the Ministry of Science, Innovation and Universities (MICINN). X.R. has received support from the SEC-CNIC CARDIOJOVEN fellowship program.es_ES
dc.relation.isversionofPublisher's versiones_ES
dc.titleCIBER-CLAP (CIBERCV Cardioprotection Large Animal Platform): A multicenter preclinical network for testing reproducibility in cardiovascular interventionses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.contributor.funderInstituto de Salud Carlos III - ISCIIIes_ES
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (España)es_ES
dc.identifier.journalScientific reportses_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Laboratorio Traslacional para la Imagen y Terapia Cardiovasculares_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Proteómica cardiovasculares_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional